In principle, any RNA molecule in the transcriptome can be inhibited using nucleic acid based drugs, using for instance antisense technology. The newest generation of such nucleic acid based drugs are self-delivering, obviating the need for a delivery vehicle to cross cell membranes in the body and bypassing a major challenge in targeted drug development.
Once inside the cell, these drugs typically display high target-specificity, being able to distinguish a single nucleotide mismatch. Compared to small molecules, rational drug development using nucleic acid based drugs has a much faster development track.
Related topics: RNA sequencing, non-coding RNA, test development, data analysis, quality, why Biogazelle, Biogazelle’s vision and mission
Speed up your antisense oligo drug development with our unique massively parallel
in vitro antisense oligo efficacy screen, using a fully optimized high-throughput workflow.
Biogazelle has extensive experience with various antisense technologies to modulate RNA expression. Through four unique modules, we provide expertise to support your antisense oligonucleotide (ASO) drug development pipeline.
Technologiepark 82
B-9052 Zwijnaarde
Belgium
email: info@biogazelle.com
phone: +32 9 245 96 43
fax: +32 9 251 56 56